Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant

References

• Alvarez A, Sanroman B, Carro E, Vazquez-Martul E. Neoplasia in solid organ transplant recipients: single-center experience. Transplant Proc 2004; 36: 784–786
   PubMed Web of Science ®Google Scholar
• Norin S, Kimby E, Ericzon B G, et al. Posttransplant lymphoma – a single-center experience of 500 liver transplantations. Med Oncol 2004; 21: 273–284
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech E, de Sanjose S, Gonzalez-Barca E, et al. Post-transplant lymphomas: a 20-year epidemiologic, clinical and pathologic study in a single center. Haematologica 2001; 86: 715–721
   PubMed Web of Science ®Google Scholar
• Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163
   PubMed Web of Science ®Google Scholar
• Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity?. J Clin Oncol 1998; 16: 2052–2059
   PubMed Web of Science ®Google Scholar
• Rajakariar R, Bhattacharyya M, Norton A, et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 2004; 4: 1534–1538
   PubMed Web of Science ®Google Scholar
• Draoua H Y, Tsao L, Mancini D M, et al. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 2004; 127: 429–432
   PubMed Web of Science ®Google Scholar
• Ghobrial I M, Habermann T M, Macon W R, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?. Transplantation 2005; 79: 244–247
   PubMed Web of Science ®Google Scholar
• Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 67–77
   PubMed Web of Science ®Google Scholar
• Leblond V, Dhedin N, Mamzer Bruneel M F, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772–778
   PubMed Web of Science ®Google Scholar
• Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant 2006; 6: 2735–2742
   PubMed Web of Science ®Google Scholar
• Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006; 134: 602–612
   PubMed Web of Science ®Google Scholar
• Choquet S, Mamzer B M, Hermine O, et al. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 67–80
   PubMedGoogle Scholar
• Bakker N A, van Imhoff G W, Verschuuren E A, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327–334
   PubMed Web of Science ®Google Scholar
• Ghobrial I M, Habermann T M, Maurer M J, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574–7582
   PubMed Web of Science ®Google Scholar
• Van Imhoff G W, Boerma E J, Van Der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135–4142
   PubMed Web of Science ®Google Scholar
• De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg lymphoma biomarker consortium. J Clin Oncol 2007; 25: 805–812
   PubMed Web of Science ®Google Scholar
• Elstrom R L, Andreadis C, Aqui N A, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569–576
   PubMed Web of Science ®Google Scholar
• Abramson J S, Shipp M A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164–1174
   PubMed Web of Science ®Google Scholar
• Tolcher A W. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol 2005; 3: 635–642, 662
   PubMedGoogle Scholar
• Kramer M H, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152–3162
   PubMed Web of Science ®Google Scholar
• Gascoyne R D, Adomat S A, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Loomis R, Carbone R, Reiss M, Lacy J. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein–Barr virus-associated lymphoproliferative disease to rituximab. Clin Cancer Res 2003; 9: 1931–1939
   PubMed Web of Science ®Google Scholar
• Shankar A, Wang J J, Rochtchina E, et al. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med 2006; 166: 188–194
   PubMedGoogle Scholar